778
Views
29
CrossRef citations to date
0
Altmetric
Review

Global Prevalence of Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis

, MSc, PhD, , PhD, , MD, , PhD & , PhD
Pages 66-75 | Received 21 Dec 2019, Accepted 09 Apr 2020, Published online: 26 Jun 2020
 

ABSTRACT

Purpose: The purpose of this study is to assess the pooled prevalence of meibomian gland dysfunction (MGD) and evaluate its risk factors by gender, age, and ethnicity.

Methods: Articles were searched reporting the prevalence of MGD from PubMed, Scopus, Web of Science, and Embase databases.

Results: The estimated pooled prevalence of MGD was 0.358 (95% CI 0.26–0.46; I2: 99.57%). The prevalence of MGD was 0.358 (95% CI 0.24–0.50) in clinical and 0.359 (95% CI 0.22–0.52) in population-based studies. Men were more prone to MGD than women (OR: 1.24, 95% CI 1.01–1.52, p = 0.034). The rate of MGD was between 21.2% and 29.5% in Africans and Caucasians, to 71.0% in Arabs, and 67.5% in Hispanics.

Conclusion: MGD is a quite prevalent disorder with an estimated pooled prevalence of 35.8%. Men are more prone to MGD than women. There is a large variation between studies in terms of quality, sample size, age ranges, diagnostic criteria, and ethnicity.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.